LEADER 03515nam 2200625 450 001 9910830371803321 005 20230721005314.0 010 $a1-4443-0333-3 010 $a1-4443-0334-1 035 $a(CKB)1000000000722805 035 $a(EBL)416357 035 $a(OCoLC)476247457 035 $a(SSID)ssj0000104238 035 $a(PQKBManifestationID)11140788 035 $a(PQKBTitleCode)TC0000104238 035 $a(PQKBWorkID)10079636 035 $a(PQKB)11394892 035 $a(MiAaPQ)EBC416357 035 $a(EXLCZ)991000000000722805 100 $a20160805h20092009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiplatelet therapy in ischemic heart disease /$fStephen D. Wiviott 210 1$aHoboken, New Jersey :$cWiley-Blackwell,$d2009. 210 4$dİ2009 215 $a1 online resource (311 p.) 225 1 $aAmerican Heart Association Clinical Series 300 $aIncludes index. 311 $a1-4051-7626-1 327 $aContents; Contributors; Preface; Foreword; PART I: Concepts in Platelet Physiology, Function, and Measurement; 1 Platelet physiology and the role of the platelet in ischemic heart disease; 2 Laboratory assessment of platelet function and the effects of antiplatelet agents; PART II: Pharmacology of Oral Antiplatelet Agents; 3 Cyclooxygenase inhibitors; 4 Aspirin response variability and resistance; 5 P2Y[sub(12)] inhibitors: Thienopyridines and direct oral inhibitors; 6 Thienopyridine response variability and resistance; PART III: Pharmacology of Intravenous Antiplatelet Agents 327 $a7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists8 Intravenous P2Y[sub(12)] inhibitors; 9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents; PART IV: Clinical Use of Antiplatelet Agents in Cardiovascular Disease; 10 Antiplatelet therapy in acute coronary syndrome without ST elevation; 11 Antiplatelet therapy in ST-elevation myocardial infarction; 12 Antiplatelet therapy in chronic coronary artery disease; 13 Antiplatelet therapy in peripheral arterial disease; 14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseases 327 $aPART V: Special Circumstances15 Antiplatelet therapy and coronary bypass surgery: risks and benefits; 16 Management of antiplatelet therapy for non-cardiac surgery; 17 Antiplatelet therapy and coronary stents; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Author Disclosure Table 330 $a* Draws from expertise of leaders in antiplatelet therapy* Easy-to-use layout enables rapid browsing* Edited by a member of the prestigious TIMI study group with long-standing experience in the field 410 0$aAmerican Heart Association monograph. 606 $aCoronary heart disease$xChemotherapy 606 $aBlood platelets$xAggregation 606 $aCoronary heart disease$xdrug therapy 615 0$aCoronary heart disease$xChemotherapy. 615 0$aBlood platelets$xAggregation. 615 0$aCoronary heart disease$xdrug therapy. 676 $a616.12306 676 $a616.123061 700 $aWiviott$b Stephen D.$01342498 701 $aWiviott$b Stephen D$01342498 712 02$aAmerican Heart Association. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830371803321 996 $aAntiplatelet therapy in ischemic heart disease$94047776 997 $aUNINA